Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sunesis Pharmaceuticals Inc.

www.sunesis.com

Latest From Sunesis Pharmaceuticals Inc.

AstraZeneca's Calquence Steps Up in First-Line CLL

A PFS benefit and favorable tolerability profile associated with AstraZeneca’s BTK inhibitor acalabrutinib used first-line in CLL, when given alone or combined with obinutuzumab, may serve it well against entrenched competitors and BTK inhibitors in clinical development.

Cancer Clinical Trials

Finance Watch: Genmab Launches This Year's Biggest Biopharma IPO In The US

Public Company Edition: Genmab raised $505.9m while other 17 July IPOs from Fulcrum and Mirum grossed $72m and $75m, respectively. Also, Horizon sells notes to pay down debt and Inovio reduces its workforce by 28%.

Business Strategies Financing

Finance Watch: Gossamer Works Around The Shutdown To Price Its $230m IPO

Gossamer took an infrequently used path to go public during a US government shutdown that's kept the SEC from processing new offerings. Also, IPO filings (and withdrawals) and follow-on offerings continued during the shutdown, while VC deals keep up a brisk pace.

Financing Business Strategies

Appointments: New Leadership At ABPI, CMOs Appointed At Acceleron and Biophytis

Pfizer's Erik Nordkamp has been named as the new president of the Association of the British Pharmaceutical Industry. Vant, Grail, Acceleron, Kite, Nimbus, Biophytis, Orchard Therapeutics, G1 Therapeutics, Almac Discovery, Athenex and Sunesis have also made key appointments.

Appointments BioPharmaceutical
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Sunesis Pharmaceuticals Inc.
  • Senior Management
  • Dayton Misfeldt, Interim CEO
    William Quinn, SVP, Fin. & Corp. Dev. & CFO
    Judith A Fox, PhD, CSO
  • Contact Info
  • Sunesis Pharmaceuticals Inc.
    Phone: (650) 266-3500
    395 Oyster Pt. Blvd.
    Ste. 400
    South San Francisco, CA 94080
    USA
UsernamePublicRestriction

Register